{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-187243","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.691685+00:00","generated_at":"2026-05-15T02:52:48.884744+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency","bullets":["Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).","Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.","No assurance given that company will meet MVLS requirement or maintain other listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-187243","json":"https://secwatch.observer/filing/0001193125-26-187243.json","markdown":"https://secwatch.observer/filing/0001193125-26-187243.md","text":"https://secwatch.observer/filing/0001193125-26-187243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/0001193125-26-187243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/d623526d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:52:48.884744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}